UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Isis Pharmaceuticals

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating on Isis Pharmaceuticals ISIS, and raised its price target from $15.00 to $18.00. Piper Jaffray noted, “ISIS is the leading antisense company with a rich pipeline of drugs in development. The primary driver for ISIS shares remains KYNAMRO with European approval this year and a January 29, 2013 PDUFA date. While ISIS shares have risen considerably since May 1st, we look for continued upside driven by KYNAMRO approval, clinical data read-outs and new partnerships. ISIS remains a Top Pick for 2H:12.” Isis Pharmaceuticals closed Tuesday at $13.74.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsPiper Jaffray & Co.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!